Jagsonpal Pharmaceuticals Ltd vs Onyx Biotec Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Jagsonpal Pharmaceuticals Ltd is ₹ 209.5 as of 06 May 15:30 . The P/E Ratio of Jagsonpal Pharmaceuticals Ltd changed from 12.2 on March 2021 to 25.9 on March 2025 . This represents a CAGR of 16.25% over 5 yearsThe P/E Ratio of Onyx Biotec Ltd changed from 21.3 on March 2025 to 21.3 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Jagsonpal Pharmaceuticals Ltd changed from ₹ 208.41 crore on March 2021 to ₹ 1433 crore on March 2025 . This represents a CAGR of 47.06% over 5 yearsThe Market Cap of Onyx Biotec Ltd changed from ₹ 105.17 crore on March 2025 to ₹ 105.17 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 67.37 crore as compare to the Dec '25 revenue of ₹ 75.92 crore. This represent the decline of -11.26% The revenue of Onyx Biotec Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Jagsonpal Pharmaceuticals Ltd for the Mar '26 is ₹ 14.33 crore as compare to the Dec '25 ebitda of ₹ 17.16 crore. This represent the decline of -16.49% The ebitda of Onyx Biotec Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Jagsonpal Pharmaceuticals Ltd changed from ₹ 5.33 crore to ₹ 8.76 crore over 8 quarters. This represents a CAGR of 28.20% The net profit of Onyx Biotec Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Jagsonpal Pharmaceuticals Ltd changed from 15.36 % on March 2021 to 29.99 % on March 2025 . This represents a CAGR of 14.32% over 5 yearsThe Dividend Payout of Onyx Biotec Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Jagsonpal Pharmaceuticals Ltd

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana.
The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs.
Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India.
It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product.
In 1994, the company has also promoted Aresco Financial Services, a new financial company.

About Onyx Biotec Ltd

Onyx Biotec Limited was incorporated as Onyx Biotec Private Limited', pursuant to a Certificate of Incorporation dated May 13, 2005 issued by the Registrar of Companies, Punjab, H.P. & Chandigarh.
Further, Company converted into a Public Limited and the name was changed to Onyx Biotec Limited' and a fresh Certificate of Incorporation dated July 23, 2024 was issued by the Registrar of Companies, Central Processing Centre. Onyx started its operation in pharmaceutical industry with sterile water for injections with capacity of 2 lacs units per day in year 2010.
Since then, Onyx is engaged in Manufacturing of Pharmaceutical Products such as sterile water ampoule, dry injection, dry syrup etc. to major corporations, which includes the top pharma companies. Presently, the Company manufactures Sterile Water for Injections, and acts as a pharmaceutical contract manufacturer offering a comprehensive range of Dry Powder Injections and Dry Syrup for India and overseas.

FAQs for the comparison of Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd

Which company has a larger market capitalization, Jagsonpal Pharmaceuticals Ltd or Onyx Biotec Ltd?

Market cap of Jagsonpal Pharmaceuticals Ltd is 1,406 Cr while Market cap of Onyx Biotec Ltd is 62 Cr

What are the key factors driving the stock performance of Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd?

The stock performance of Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd?

As of May 6, 2026, the Jagsonpal Pharmaceuticals Ltd stock price is INR ₹209.5. On the other hand, Onyx Biotec Ltd stock price is INR ₹34.7.

How do dividend payouts of Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd compare?

To compare the dividend payouts of Jagsonpal Pharmaceuticals Ltd and Onyx Biotec Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.